Risks
4 risks
Risk Intelligence
Geopolitical cost headwinds
View Risks →Sai Life Sciences Limited — Q4 FY26
Sai Life Sciences delivered a strong FY26 with 29% revenue growth, 56% EBITDA growth, and 109% PAT growth, driven by deepening large pharma relationships (19 of top 25, contributing 49% of revenue vs 28% in FY22) and balanced CRO/CDMO performance.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Sai Life Sciences delivered a strong FY26 with 29% revenue growth, 56% EBITDA growth, and 109% PAT growth, driven by deepening large pharma relationships (19 of top 25, contributing 49% of revenue vs 28% in FY22) and balanced CRO/CDMO performance. The CDMO segment grew 33%, CRO 24%. Management reiterated a 15-20% revenue growth and 28-30% EBITDA margin guidance over three years, but flagged near-term headwinds from geopolitical tensions impacting input costs and logistics. A sharp capex increase to ₹1,100-1,300 crore in FY27 (vs ₹633 crore in FY26) reflects strong demand visibility from strategic customer partnerships, with 75% allocated to capacity expansion. However, execution risk remains as new capacities come online, with H2 expected stronger than H1. The key risk is that cost recovery from customers may lag cost increases, pressuring margins.
साई लाइफ साइंसेज ने FY26 में शानदार प्रदर्शन किया। कमाई 29% बढ़ी, मुनाफा (EBITDA) 56% बढ़ा और शुद्ध मुनाफा (PAT) 109% बढ़ा। इसकी वजह बड़ी दवा कंपनियों से गहरे संबंध हैं। अब शीर्ष 25 में से 19 कंपनियां इसकी ग्राहक हैं, जो 49% कमाई देती हैं। कंपनी ने अगले तीन सालों में 15-20% कमाई और 28-30% मुनाफा मार्जिन का लक्ष्य रखा है। लेकिन भू-राजनीतिक तनाव से लागत और आपूर्ति पर असर पड़ सकता है। FY27 में पूंजी निवेश बढ़ाकर ₹1,100-1,300 करोड़ किया जाएगा, जिसमें 75% क्षमता बढ़ाने पर खर्च होगा। हालांकि, नई क्षमताओं से जुड़ा जोखिम है और लागत वसूली में देरी से मुनाफा कम हो सकता है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Large pharma revenue contribution
49%
+21pp vs FY22
Revenue from top 19 large pharma clients increased from 28% in FY22 to 49% in FY26, showing deepening strategic relationships.
Commercial molecules pipeline
34
+4 vs Q3 FY26
Commercial molecules increased to 34, with 11 in phase III/pre-registration, indicating strong late-stage pipeline.
Top 10 customer concentration
54%
N/A
Top 10 customers contributed 54% of revenue, with top 5 at 37% and top 1 at 12%, showing manageable concentration.
Capex guidance FY27
₹1,100-1,300 Cr
+74% vs FY26 actual of ₹633 Cr
Capex nearly doubles to support capacity expansion (75%) and capability/technology (25%), driven by customer demand visibility.
Fast read
Guidance and risk preview
Management reiterated long-term revenue growth guidance of 15-20% CAGR, supported by strong pharma relationships and pipeline.
Input cost inflation and logistics disruptions from geopolitical tensions may not be fully recovered from customers in a timely manner, pressuring...
View Risks →